Testosterone transdermal - Elan Pharma

Drug Profile

Testosterone transdermal - Elan Pharma

Latest Information Update: 12 Dec 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Elan Pharma International
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Eye disorder therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Menopausal syndrome

Most Recent Events

  • 23 Jan 2015 Biomarkers information updated
  • 12 Dec 2006 Discontinued - Clinical-Phase-Unknown for Menopausal syndrome in United Kingdom (Transdermal)
  • 24 Jun 1999 Investigation in Menopausal syndrome in United Kingdom (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top